Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

Corcept Therapeutics (CORT) Tops Q4 EPS by 3c

February 8, 2021 4:12 PM EST

Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $85.7 million versus the consensus estimate of $90.36 million.

GUIDANCE:

2021 revenue guidance $375 - 405 million

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

... More